Amylyx Pharmaceuticals, Inc. (AMLX)

$2

-0.12

(-5.66%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $2.00
    $2.17
    $2.00
    downward going graph

    0.0%

    Downside

    Day's Volatility :7.83%

    Upside

    7.83%

    downward going graph
  • $1.58
    $25.48
    $2.00
    downward going graph

    21.0%

    Downside

    52 Weeks Volatility :93.8%

    Upside

    92.15%

    downward going graph

Returns

PeriodAmylyx Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
7.07%
8.7%
0.0%
6 Months
-85.75%
8.0%
0.0%
1 Year
-90.51%
14.0%
0.0%
3 Years
-88.27%
17.0%
-18.2%

Highlights

Market Capitalization
144.2M
Book Value
$4.77
Earnings Per Share (EPS)
-1.07
Wall Street Target Price
4.25
Profit Margin
-17.86%
Operating Margin TTM
-137.78%
Return On Assets TTM
-12.31%
Return On Equity TTM
-21.0%
Revenue TTM
398.0M
Revenue Per Share TTM
5.9
Quarterly Revenue Growth YOY
24.099999999999998%
Gross Profit TTM
-74.2M
EBITDA
-80.1M
Diluted Eps TTM
-1.07
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.97
EPS Estimate Next Year
-1.36
EPS Estimate Current Quarter
-0.01
EPS Estimate Next Quarter
-0.7

Analyst Recommendation

Buy
    53%Buy
    46%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Amylyx Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
8
13
Hold
6
6
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 112.5%

Current $2.00
Target $4.25

Company Financials

FY19Y/Y Change
Revenue
1.4M
-
Net Income
-14.8M
-
Net Profit Margin
-1.0K%
-
FY20Y/Y Change
Revenue
650.0K
↓ 54.42%
Net Income
-44.8M
↑ 202.63%
Net Profit Margin
-6.9K%
↓ 5859.01%
FY21Y/Y Change
Revenue
285.0K
↓ 56.15%
Net Income
-87.9M
↑ 96.0%
Net Profit Margin
-30.8K%
↓ 23936.74%
FY22Y/Y Change
Revenue
22.2M
↑ 7700.0%
Net Income
-198.4M
↑ 125.74%
Net Profit Margin
-892.38%
↑ 29942.36%
FY23Y/Y Change
Revenue
380.8M
↑ 1612.94%
Net Income
49.3M
↓ 124.84%
Net Profit Margin
12.94%
↑ 905.32%
Q4 FY22Q/Q Change
Revenue
21.9M
↑ 6243.48%
Net Income
-42.7M
↓ 20.56%
Net Profit Margin
-195.13%
↑ 15386.32%
Q1 FY23Q/Q Change
Revenue
71.4M
↑ 226.38%
Net Income
1.6M
↓ 103.68%
Net Profit Margin
2.2%
↑ 197.33%
Q2 FY23Q/Q Change
Revenue
98.2M
↑ 37.5%
Net Income
22.1M
↑ 1303.31%
Net Profit Margin
22.47%
↑ 20.27%
Q3 FY23Q/Q Change
Revenue
102.7M
↑ 4.56%
Net Income
20.9M
↓ 5.35%
Net Profit Margin
20.35%
↓ 2.12%
Q4 FY23Q/Q Change
Revenue
108.4M
↑ 5.61%
Net Income
4.7M
↓ 77.36%
Net Profit Margin
4.36%
↓ 15.99%
Q1 FY24Q/Q Change
Revenue
88.6M
↓ 18.26%
Net Income
-118.8M
↓ 2610.95%
Net Profit Margin
-134.01%
↓ 138.37%
FY19Y/Y Change
Total Assets
3.2M
-
Total Liabilities
28.6M
-
FY20Y/Y Change
Total Assets
14.1M
↑ 338.01%
Total Liabilities
80.8M
↑ 182.85%
FY21Y/Y Change
Total Assets
105.6M
↑ 648.82%
Total Liabilities
256.8M
↑ 217.69%
FY22Y/Y Change
Total Assets
391.5M
↑ 270.64%
Total Liabilities
50.8M
↓ 80.2%
FY23Y/Y Change
Total Assets
517.5M
↑ 32.19%
Total Liabilities
84.0M
↑ 65.25%
Q4 FY22Q/Q Change
Total Assets
391.5M
↑ 115.74%
Total Liabilities
50.8M
↑ 35.9%
Q1 FY23Q/Q Change
Total Assets
408.0M
↑ 4.22%
Total Liabilities
55.3M
↑ 8.78%
Q2 FY23Q/Q Change
Total Assets
453.6M
↑ 11.18%
Total Liabilities
67.2M
↑ 21.54%
Q3 FY23Q/Q Change
Total Assets
466.6M
↑ 2.87%
Total Liabilities
48.2M
↓ 28.32%
Q4 FY23Q/Q Change
Total Assets
517.5M
↑ 10.9%
Total Liabilities
84.0M
↑ 74.38%
Q1 FY24Q/Q Change
Total Assets
417.5M
↓ 19.32%
Total Liabilities
93.0M
↑ 10.71%
FY19Y/Y Change
Operating Cash Flow
-10.7M
-
Investing Cash Flow
-151.0K
-
Financing Cash Flow
668.0K
-
FY20Y/Y Change
Operating Cash Flow
-36.7M
↑ 243.38%
Investing Cash Flow
-151.0K
↑ 0.0%
Financing Cash Flow
46.8M
↑ 6909.43%
FY21Y/Y Change
Operating Cash Flow
-74.8M
↑ 103.83%
Investing Cash Flow
-46.4M
↑ 30632.45%
Financing Cash Flow
158.5M
↑ 238.52%
FY22Y/Y Change
Operating Cash Flow
-179.9M
↑ 140.47%
Investing Cash Flow
-239.0M
↑ 414.99%
Financing Cash Flow
431.8M
↑ 172.41%
Q4 FY22Q/Q Change
Operating Cash Flow
-49.7M
↑ 15.37%
Investing Cash Flow
-228.2M
↓ 371.51%
Financing Cash Flow
232.2M
↑ 16.3%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.1M
↓ 89.79%
Investing Cash Flow
56.0M
↓ 124.54%
Financing Cash Flow
1.0M
↓ 99.55%
Q2 FY23Q/Q Change
Operating Cash Flow
8.6M
↓ 269.74%
Investing Cash Flow
123.2M
↑ 120.06%
Financing Cash Flow
1.4M
↑ 33.08%

Technicals Summary

Sell

Neutral

Buy

Amylyx Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
30.86%
-85.75%
-90.51%
-88.27%
-88.27%
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
2.51
NA
NA
-2.97
-0.21
-0.12
NA
4.77
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
Buy
$144.2M
-88.27%
2.51
-17.86%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on Amylyx Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 108.44M → 88.64M (in $), with an average decrease of 18.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 22.07M → -118.79M (in $), with an average decrease of 897.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 69.0% return, outperforming this stock by 159.5%

Institutional Holdings

  • Vanguard Group Inc

    7.86%
  • BlackRock Inc

    6.58%
  • Goldman Sachs Group Inc

    4.33%
  • Millennium Management LLC

    3.63%
  • Morgan Stanley - Brokerage Accounts

    3.04%
  • State Street Corporation

    3.03%

Company Information

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.

Organization
Amylyx Pharmaceuticals, Inc.
Employees
384
CEO
Mr. Joshua B. Cohen
Industry
Services

FAQs